Meta-analysis of quality of life in patients with cancer treated with antibody-drug conjugates in randomized controlled trials

被引：0
|
作者：
Qiu, Tianlei [1 ,2 ]
Shen, Guoshuang [1 ,2 ]
Xin, Yuanfang [1 ,2 ]
Li, Jinming [1 ,2 ]
Zheng, Yonghui [1 ,2 ]
Zhu, Zijun [1 ,2 ]
Zhang, Chengrong [1 ,2 ]
Tang, Yuyao [1 ,2 ]
Wang, Miaozhou [1 ,2 ]
Liu, Zhen [1 ,2 ]
Zhao, Yi [1 ,2 ]
Zhao, Fuxing [1 ,2 ]
Ren, Dengfeng [1 ,2 ]
Li, Huihui [3 ]
Liu, Yaobang [4 ]
Liu, Xinlan [4 ]
Zhao, Jiuda [1 ,2 ]
机构：
[1] Qinghai Univ, Affiliated Hosp, Breast Dis Diag & Treatment Ctr, Xining 810000, Peoples R China
[2] Qinghai Univ, Affiliated Canc Hosp, Xining 810000, Peoples R China
[3] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Breast Med Oncol, Jinan 250117, Peoples R China
[4] Ningxia Med Univ, Gen Hosp, Dept Surg Oncol, Yinchuan 750000, Peoples R China
来源：
FUTURE ONCOLOGY | 2023年
关键词：
antibody-drug conjugates; anticancer drug; chemotherapy; meta-analysis; oncology; outcome measures; patient-reported outcomes; quality of life; targeted therapy; time to deterioration; TRASTUZUMAB EMTANSINE; REPORTED OUTCOMES; AMERICAN SOCIETY; PHASE-III; FRAMEWORK;
D O I：
10.2217/fon-2023-0253
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose: To evaluate the patient-reported outcomes of patients treated with commercially approved antibody-drug conjugates (ADC) reported in randomized controlled trials (RCT) published up to September 2023. Methods: A meta-analysis of 6430 patients from 12 randomized controlled trials was conducted. Results: No significant change was observed between the groups from baseline to end of treatment and end of follow-up, with a standardized mean difference of -0.08 (95% CI: -0.27-0.12) and 0.01 (95% CI: -0.11-0.12), respectively. Treatment with ADCs delayed the deterioration of patients' clinical condition compared with treatment with non-ADCs, with a hazard ratio of 0.78 (95% CI: 0.67-0.92). Conclusion: ADCs have a good correlation with delay of clinical deterioration in patients with cancer.
引用
收藏
页码：2201 / 2212
页数：12
相关论文
共 50 条
  • [1] Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials
    Fu, Zhiwen
    Gao, Chen
    Xie, Jiyi
    Zhang, Cong
    Li, Shijun
    Gu, Ming
    Shi, Chen
    BMC CANCER, 2023, 23 (01)
  • [2] Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis
    Boutros, Andrea
    Bruzzone, Marco
    Tanda, Enrica T.
    Croce, Elena
    Arecco, Luca
    Cecchi, Federica
    Pronzato, Paolo
    Ceppi, Marcello
    Lambertini, Matteo
    Spagnolo, Francesco
    EUROPEAN JOURNAL OF CANCER, 2021, 159 : 154 - 166
  • [3] Adverse events and impact on quality of life of antibody-drug conjugates in the treatment of metastatic breast cancer: A systematic review and meta-analysis
    Perachino, Marta
    Blondeaux, Eva
    Molinelli, Chiara
    Ruelle, Tommaso
    Giannubilo, Irene
    Arecco, Luca
    Nardin, Simone
    Razeti, Maria Grazia
    Borea, Roberto
    Favero, Diletta
    Lanzavecchia, Chiara
    Chiappe, Edoardo
    Tomasello, Loredana
    Mariamidze, Elene
    Jankovic, Kristina
    Stana, Mihaela
    Ottonello, Silvia
    Scavone, Graziana
    de Moura Leite, Luciana
    Spinaci, Stefano
    Saura, Cristina
    Lambertini, Matteo
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2025,
  • [4] Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials
    Zhiwen Fu
    Chen Gao
    Jiyi Xie
    Cong Zhang
    Shijun Li
    Ming Gu
    Chen Shi
    BMC Cancer, 23 (1)
  • [5] Quality of life in ovarian cancer patients treated with bevacizumab: a meta-analysis
    Wu, Di
    He, Jianrong
    Shi, Ping
    Wang, Zirong
    Liu, Min
    Liu, Anchang
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (03) : 269 - 276
  • [6] Effects of yoga on improving quality of life in patients with breast cancer: a meta-analysis of randomized controlled trials
    Hsueh, Er-Jung
    Loh, El-Wui
    Lin, Joyce Jui-An
    Tam, Ka-Wai
    BREAST CANCER, 2021, 28 (02) : 264 - 276
  • [7] Effects of yoga on improving quality of life in patients with breast cancer: a meta-analysis of randomized controlled trials
    Er-Jung Hsueh
    El-Wui Loh
    Joyce Jui-An Lin
    Ka-Wai Tam
    Breast Cancer, 2021, 28 : 264 - 276
  • [8] Investigational antibody-drug conjugates in clinical trials for the treatment of breast cancer
    Okines, Alicia F. C.
    Ulrich, Lara
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (08) : 789 - 795
  • [9] Toxicity profiles of antibody-drug conjugates for anticancer treatment: a systematic review and meta-analysis
    Suzuki, Yukio
    Zhou, Susu
    Ota, Yukihide
    Harrington, Matthew
    Miyagi, Etsuko
    Takagi, Hisato
    Kuno, Toshiki
    Wright, Jason D.
    JNCI CANCER SPECTRUM, 2023, 7 (05)
  • [10] Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis
    Zhu, Youwen
    Liu, Kun
    Wang, Kailing
    Zhu, Hong
    CANCER, 2023, 129 (02) : 283 - 295
12345